Related Experiment Videos
Childhood rhabdomyosarcoma: experience of the Children's Solid Tumour Group
Insights
Rhabdomyosarcoma prognosis significantly depends on disease extent at diagnosis. Early-stage tumors show an 86% survival rate, while advanced tumors have only a 21% survival rate, highlighting the importance of early detection.
Area of Science:
- Pediatric Oncology
- Cancer Research
- Clinical Trials
Background:
- Rhabdomyosarcoma is a rare childhood cancer.
- Treatment protocols have evolved over time.
- Prognostic factors require continuous evaluation.
Purpose of the Study:
- To analyze the prognostic factors influencing rhabdomyosarcoma outcomes in children.
- To evaluate the effectiveness of treatment protocols.
- To identify predictors of treatment response and relapse.
Main Methods:
- Retrospective analysis of 73 children with rhabdomyosarcoma treated between 1974-1981.
- Assessment of disease extent (confined vs. unconfined) at diagnosis.
- Evaluation of histological type, primary tumor site, and treatment response.
Main Results:
- Disease extent at diagnosis was the primary prognostic factor: 86% 5-year survival for confined tumors vs. 21% for unconfined tumors.
- Overall complete response rate was 77%.
- Salvage rate for relapsed patients was 15%, with late relapses observed in 5 children, particularly those with paratesticular tumors.
Conclusions:
- Early diagnosis and localized disease are critical for favorable rhabdomyosarcoma outcomes in children.
- Treatment protocols achieved a high initial response rate, but relapse remains a significant challenge.
- Further research is needed to improve salvage rates and understand late relapse patterns.
Abstract:
Seventy three children with rhabdomyosarcoma were treated by members of the Children's Solid Tumour Group during the period, 1974-1981. The extent of disease at diagnosis was found to be the major influence affecting outcome. Children with tumours confined to the tissue of origin with no evidence of nodal or metastatic spread, had a predicted actuarial 5-year survival rate of 86%. However children with 'unconfined' tumours, i.e. those with extension of disease outside the tissue of origin, had a much poorer prognosis with an actuarial 5-year survival rate of only 21%. Two other factors, histological type and site of primary tumour, appeared to affect prognosis but were not independent of the extent of disease at diagnosis. All children were treated according to protocol. Fifty-two patients showed a complete response to initial therapy and 4 of the 11 partial responders achieved a full remission after additional therapy. The overall complete response rate was therefore 77%. Nineteen children who achieved a complete response on initial treatment subsequently relapsed. Only 3 of these children were alive with no evidence of disease 3 years later, a salvage rate of 15%. "Late" relapses, defined as those occurring more than 2 years after diagnosis, were seen in only 5 children, 4 in boys with primary paratesticular tumours.